GREY:IMVIF - Post by User
Comment by
alphaseeking001on Mar 26, 2019 10:45am
97 Views
Post# 29536400
RE:RE:Thoughts on prelim data
RE:RE:Thoughts on prelim dataI agree with your points. Happy that the pullback was not based on poor clinical results... in fact, early monotherapy results are pointing in a very good direction. But... as you said. It's time that management produces shareholder value commensurate with the results. Seriously. There is no need for the stock price to be down here with these kind of continued good clinical results.
On another point regarding future financings (and take what they said with a grain of salt), I was led to believe in speaking with management after this financing that they are hoping to not need to do another financing at all if clinical results continue to unfold similar to today's. In other words I believe they are hoping to bring in cash flow with DPX-Survivac either through licensing deal(s) or selling the company outright at some point before they need more funds. But... as I said, take that with a grain of salt.